By David Bautz, PhDNASDAQ:MTPREAD THE FULL MTP RESEARCH REPORTFinancial UpdateOn April 24, 2019, Midatech Pharma (NASDAQ:MTP) announced financial results for 2018. The company generated total gross revenue of £1.94 million, which included both collaboration income and grant revenue. R&D expenses in 2018 were £9.4 million compared to £8.3 million...
By David Bautz, PhDNASDAQ:MNOVREAD THE FULL MNOV RESEARCH REPORTBusiness UpdateReady to Move MN-166 into Phase 3 Trial in ALSOn April 15, 2019, MediciNova, Inc. (NASDAQ:MNOV) announced that following review of the protocol the U.S. Food and Drug Administration (FDA) has determined that the company may proceed with the Phase...
By John Vandermosten, CFAOTC:PMN.TO | OTC:ARFXF ProMIS Neurosciences Inc. (OTC:PMN.TO) holds an enviable position in the drug development universe. The scientists leading the company have been able to merge chemistry, biology and physics to optimize drug design by employing proprietary algorithms that are able to identify high probability conformations...
By John Vandermosten, CFANASDAQ:VVUSREAD THE FULL VVUS RESEARCH REPORT We are initiating coverage of VIVUS, Inc. (NASDAQ:VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic insufficiency (EPI) and erectile dysfunction (ED) solutions, Vivus maintains...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdatePhase 2b Trial for VK2809 to Initiate 2H19Viking Therapeutics, Inc. (NASDAQ:VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). A...
By Brian Marckx, CFAOTC:SMLRREAD THE FULL SMLR RESEARCH REPORTQ1 2019 Results: Record Revenue, EPS. Cash Flow Increasing. Infrastructure Investments Based on Demand…Semler Scientific (OTC:SMLR) reported financial results for their first quarter ending March 31, 2019. Revenue was about 2% better than our estimate, up nearly 52% from the...
By Lisa ThompsonNASDAQ:MOGOREAD THE FULL MOGO RESEARCH REPORT Mogo (NASDAQ:MOGO) is a rapidly growing Canadian fintech company with over 800K members that generates revenues from a series of innovative products to help consumers manage & control their financial health. These products include a digital spending account with a Platinum Prepaid Visa Card, ID Fraud protection...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateAdditional Data Presented for Exebacase Phase 2 TrialOn April 16, 2019, Contrafect Corp. (NASDAQ:CFRX) announced the presentation of new data from the Phase 2 clinical trial of exebacase (CF-301) for the treatment of Staphylococcus aureus bacteremia including endocarditis at the...
NASDAQ:CKPT Checkpoint Therapeutics (NASDAQ:CKPT) will be releasing highly anticipated interim data from its Phase I clinical trial this quarter. The readout will be for CK-301, an anti-PD-L1 antibody, which is expected to include safety and efficacy data from approximately 40-50 patients with a variety of tumor types...
By Steven Ralston, CFAOTC:ALPEREAD THE FULL ALPE RESEARCH REPORT alpha-En Corp (OTC:ALPE) is a technology development company, primarily focusing on the development of a commercially viable process for the production of high-purity lithium metal and of a thin film lithium anode for use in the next generation of lithium high-energy...